Hinge Health, Progyny partnership ‘mutually beneficial,’ says Morgan Stanley

After Progyny (PGNY) announced that it is adding pelvic floor therapy to its offering of women’s health and family building solutions and noted that it welcomed Origin and Hinge Health (HNGE) to its offering, Morgan Stanley said the firm sees this as “a mutually beneficial partnership.” The addition of Progyny to Hinge’s network should help drive yield expansion, according to the analyst, who adds that Hinge is already seeing strong momentum in Women’s Pelvic Health and positive initial feedback on the launch of a menopause program in Q1. Morgan Stanley has an Overweight rating and $46 price target on Hinge Health shares.